TUESDAY, OCTOBER 24, 2017

Streptococcus vaccine clinical trial begins

Streptococcus vaccine clinical trial launches
Streptococcus vaccine clinical trial launches | Courtesy of biothreatsmitre.org

The Pan-Provincial Vaccine Enterprise, Inc. (PREVENT) and Vaxent announced Tuesday that they have launched their Phase 1 clinical trial for StreptAnova, a vaccine engineered to protect people against Group A streptococcal (GAS) infections.

PREVENT is a national Centre of Excellence for Commercialization and Research (CECR) based at the University of Saskatchewan. Vaxent is located in Memphis, Tennessee. The trial will be carried out in Halifax, Nova Scotia, at the Canadian Center for Vaccinology.

The purpose of the trial is to determine the safety and effectiveness of the new vaccine.

Group A streptococcal diseases are typically found in children rather than adults. It results in increased mortality and morbidity, causing illness from strep throat to blood infections to flesh-eating disease to blood infections.

“We are very excited by this collaborative partnership with Vaxent to advance the development of this novel StreptAnova multivalent vaccine,” PREVENT CEO and Director of VIDO-InterVac at the University of Saskatchewan Andrew Potter said. “It represents a significant milestone in PREVENT’s commercialization success working together with partners to accelerate the commercial development of innovative vaccine candidates. The availability of a safe and effective multivalent GAS vaccine could address a huge unmet public health demand, preventing a wide variety of potentially life-threatening complications and diseases in humans worldwide attributable to this organism.”